Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action

April 29, 2024

https://www.globenewswire.com/news-release/2024/04/29/2871424/0/en/Molecular-Partners-Announces-Publication-in-Cancer-Immunology-Research-of-Preclinical-Data-Supporting-MP0533-s-Proposed-Mechanism-of-Action.html

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 29, 2024 (GLOBE NEWSWIRE) — Molecular Partners AG (SIX: MOLN; NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced a comprehensive, peer-reviewed publication of preclinical data supporting MP0533’s proposed unique mechanism of action (MoA) for the treatment of acute myeloid leukemia (AML) in Cancer Immunology Research, a journal of the American Association for Cancer Research. The publication collates and discusses multiple studies undertaken to characterize MP0533’s preclinical profile and evaluate its therapeutic potential.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.